CLINICAL Cell Culture (C3) commercially launched its CellSpray XP product in Europe this week.
The local company expects the first patients to be treated with the product by the end of June or early July this year.
C3 estimates the European market potential for the products to be approximately 10,000 patients a year.
Using proprietary tissue-culture technology, C3 provides treatment solutions derived from a patient’s own skin to enhance healing rates, reduce scar formation and reintroduce pigmentation to the skin.